Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
暂无分享,去创建一个
[1] D. Larenas-Linnemann,et al. Update on Omalizumab for Urticaria: What’s New in the Literature from Mechanisms to Clinic , 2018, Current Allergy and Asthma Reports.
[2] J. Simon,et al. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] E. González-Guerra,et al. Effectiveness of omalizumab in a case of urticarial vasculitis , 2017, Clinical and experimental dermatology.
[4] Misbah Ghazanfar,et al. Omalizumab for Urticarial Vasculitis: Case Report and Review of the Literature , 2015, Case reports in dermatological medicine.
[5] Z. Fedorowicz,et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment , 2015, The British journal of dermatology.
[6] J. Hébert,et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] R. Cardona,et al. [Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases]. , 2013, Biomedica : revista del Instituto Nacional de Salud.
[8] J. G. Vera,et al. 274 Vasculitic Urticaria Treated with Omalizumab. Case Report , 2012, The World Allergy Organization Journal.
[9] M. Triggiani,et al. 275 Efficacy of Omalizumab in the Treatment of Urticaria-Vasculitis Associated to Churg-Strauss Syndrome: A Case Report , 2012, The World Allergy Organization Journal.
[10] B. Wilson,et al. Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy , 2009, International Archives of Allergy and Immunology.
[11] D. Huston,et al. Urticarial vasculitis , 1995, Clinical reviews in allergy & immunology.